Your partner in metabolomics
Metabolomics company
Your partner in metabolomics
The
company
We are OWL Metabolomics, your supply partner in the world of metabolomic analysis. Our commitment is guiding you from sample to profound insights, making biological sense out of complex data with our comprehensive reports and powerful data analytics technologies. With our specialized expertise in metabolite profiling, we support and accelerate your research journey, ensuring your success by addressing your scientific questions, research, and diagnostic needs.
Supporting research success
About us
As a pioneer metabolomics company at the forefront of biotechnological innovation, we have more than 18 years of experience. As part of Rubió Group, we work closely to align our companies’ R&D efforts. We pursue understandable and actionable insights through metabolomics profiling to achieve useful breakthroughs for scientific exploration and discovery.
Purpose
- At OWL Metabolomics we have a clear focus on using metabolomics to bring forward discoveries that can improve patient lives. Our clients will encounter a committed team to work together to turn complex science into real-world solutions.
Vision
- We see a future where our work in metabolomics leads to big improvements across many areas of knowledge, society and the world. Guided by trust, teamwork, and a clear idea of how the future should look like, we aim to make a better life for patients, physicians and researchers.
Innovative Ecosystem
Business
Environment
Situated in the heart of the Parque Tecnológico de Bizkaia, OWL Metabolomics, is an important part of a growing environment for scientific research and innovation. This unique hub promotes the blending of various areas of expertise, such as molecular biology, genetics, metabolite profiling, engineering, nanotechnology, electronics, robotics, and others.
As an integral part of this dynamic business environment of over 286 R&D-focused entities, we utilize our expertise in molecular biology genetics and metabolite profiling to push the boundaries of science and drive progress.
Notable achievements
Milestones
per year
2002
OWL Metabolomics was founded.
2004
The company began its operations.
2006
The Metabolomics department was established.
2009
Accreditation as a diagnostic center. New laboratories inaugurated.
2011
ISO 9001 Quality Certification.
2012
First project with a non-Spanish pharmaceutical company.
2015
First participation in a clinical trial.
2017
CE Certification of the first version of OWLiver®.
2018
ISO 13485 Quality Certification.
2019
Marketing association of OWLiver® with Laboratorios Rubió.
2020
CE Certification of OWLiver® F2+.
2021
CE Certification of OWLiver® DM2.
2023
OWL Metabolomics joined the Rubió Group. We combine liver research with exploring broader R&D applications for metabolomics in various industries.
2004
The company began its operations.
2009
Accreditation as a diagnostic center. New laboratories inaugurated.
2012
First project with a non-Spanish pharmaceutical company.
2017
CE Certification of the first version of OWLiver®.
2019
Marketing association of OWLiver® with Laboratorios Rubió.
2021
CE Certification of OWLiver® DM2.
2002
OWL Metabolomics was founded.
2006
The Metabolomics department was established.
2011
ISO 9001 Quality Certification.
2015
First participation in a clinical trial.
2018
ISO 13485 Quality Certification.
2020
CE Certification of OWLiver® F2+.
2023
OWL Metabolomics joined the Rubió Group. We combine liver research with exploring broader R&D applications for metabolomics in various industries.
Proven record
Track
Record
Since 2006 we have established a strong track record in the field of metabolomics. Throughout our journey, we have successfully completed more than 350 service projects. Through these years we have led and been involved in a great number of R&D projects in a continuous dedication to advance scientific knowledge, contributing to the monitoring and diagnosis of human and animal health. Our work is endorsed by a great number of peer-reviewed scientific articles published.
Dedicated Professionals
Our team
Management Team
Miguel Campo
Miguel Campo has a Bachelor’s degree in Pharmacy from the Madrid Complutense University (UCM) and a Master’s degree in Sales and Marketing Management in Pharmaceutical and Related Industries. Miguel has more than 23 years of experience as a Business Development Manager in the pharmaceutical industry, in different CROs. His experience spans across multiple therapeutic areas, including Oncology, Respiratory, Cardiovascular, Haematology, Vaccines and Neurology. Miguel has joined OWL Metabolomics in 2023 as a Business Development Manager.
Miguel Campo
Business Development ManagerMore info
Haroon Allybacus
Haroon Allybacus has a Bachelor’s degree in Chemistry and an MBA specialising in international marketing. Haroon has over 20 years of unparalleled success & experience in international sales and business development in the Life Sciences industry. Notably, he has over 10 years experience in both the NMR and Mass Spec metabolomics space and is a powerful results orientated leader, consistently recognised as a top achiever with a proven track record of success. His unique resume is complemented with an understanding and passion of physiology, chronic disease management and human health.
Haroon Allybacus
Business Development Manager UK & EUMore info
Toni Felís Soto
Toni Felís Soto, Bachelor of Business Administration graduate from the Universitat Autònoma de Barcelona and an Executive Masters in Finance from the ESADE Business & Law School, started his professional journey as an auditor at PricewaterhouseCoopers. In 2008, he joined Laboratorios Rubió, leading the Treasury, Accounting, and Legal departments for fourteen years. His comprehensive skillset has fostered an in-depth understanding of the pharmaceutical industry, enhancing his customer-oriented approach. Currently, he serves as the Business Unit Manager at OWL Metabolomics, leading the team of people that make up the organization.
Toni Felís Soto
Business Unit ManagerMore info
Ane Castilla
Ane Castilla holds a Bachelor’s degree in Biochemistry from the University of the Basque Country (UPV/EHU) and a Master’s degree in Toxicology and Contamination. She joined OWL Metabolomics in 2023, contributing her experience in both the clinical and agrifood sectors to navigate regulatory frameworks with a broad perspective and deep understanding of normative and regulatory requirements in highly regulated sectors.
Her career includes significant contributions in laboratories, as well as serving as an evaluator at the National Accreditation Body (ENAC). This extensive experience provides unique insight into the complexities of quality management and regulatory compliance, enhancing OWL Metabolomics’ potential for excellence.
Ane Castilla
QA & Regulatory Affairs ManagerMore info
Cristina Alonso, PhD
Cristina Alonso completed a BSc degree in Chemistry from the University of Valladolid and a PhD in Analytical Chemistry. She joined OWL Metabolomics in 2007 as a Chromatography and Mass Spectrometry Specialist, and currently serves as the Services Manager and Head of the Data Processing Department. In her role, she trains Data Processing Specialists and provides technical support for the company’s R&D.
Dr. Alonso scientific career has been focused on processing and interpretation of mass spectrometry-based metabolomic data, dedicated to the search for non-invasive biomarkers for liver diseases diagnosis and drug effect in MASH clinical trials. She has contributed to over 70 scientific publications in high impact journals.
(Researcher unique identifier: https://orcid.org/0000-0002-2019-678X).
Cristina Alonso, PhD
Services Manager & Head of the Data Processing DepartmentMore info
Ibon Martinez Arranz
Ibon Martínez-Arranz, with a BSc degree in Mathematics, an MSc in Applied Statistical Techniques, and an MSc in Mathematical Modeling, joined OWL Metabolomics in 2010. Since 2017, he has been the Data Science Manager at OWL Metabolomics, overseeing prediction and statistical computing management. His team supports metabolomic services, data handling, and research and development projects. Currently, Martínez-Arranz is finalizing his doctoral thesis on the application of genetic algorithms for the selection of MASLD subtypes.
(Researcher unique identifier: https://orcid.org/0000-0001-9483-8426).
Ibon Martinez Arranz
Data Science ManagerMore info
Rebeca Mayo, PhD
Rebeca Mayo received her BSc degree in Chemistry from the University of Valladolid, where she also completed her PhD in Analytical Chemistry. In 2009 she joined OWL Metabolomics as a Chromatography and Mass Spectrometry Specialist in the Metabolomics Department. In 2012 she became part of the Management Team as Laboratory and Metabolomics Platform Manager. Since 2015, she has been the Head of Products Area, being actively involved in developing the in vitro diagnostic medical devices developed by OWL Metabolomics and their compliance with regulations.
Currently, Dr. Mayo is the Operations Manager, overseeing lab operations, R&D activities, and technology transfer processes. As one of the principal scientists at OWL Metabolomics, she is co-author of more than 20 scientific publications.
(Researcher unique identifier: https://orcid.org/0000-0001-9733-2121).
Rebeca Mayo, PhD
Operations ManagerMore info
SAB (Scientific Advisory BoARD)
Jesús Bañales, PhD
Dr. Jesús Bañales is an Ikerbasque Research Professor and the Head of the Hepatic Diseases Group at the Biodonostia Health Research Institute – Donostia University Hospital, in San Sebastián. In addition, he is a Professor of Biochemistry at the University of Navarra (Pamplona), as well as an Associate Professor of Medicine/Sciences at Mayo Clinic (Rochester, USA) and the Universidad Área Andina (Bogotá, Colombia).
His Hepatic Diseases Research Group consists of 25 multidisciplinary researchers focused on studying the molecular mechanisms involved in liver pathophysiology and the search for new diagnostic and therapeutic strategies.
Prof. Bañales is the author of more than 200 scientific publications in high-impact journals and has led more than 50 competitive national and international research projects. He is a member of the Editorial Board of the scientific journals Hepatology, Journal of Hepatology (Associate Editor) and Nature Reviews Gastroenterology & Hepatology. He has been recognized with various international research awards, such as the EASL Emerging Leader Award 2018, UEG Rising Star Award 2018, and “SER Navarra Researcher Award” 2020.
Jesús Bañales, PhD
More info
Dina Ferreira
Dina Ferreira has a Bachelor’s and Master’s Degree in Pharmacy from the Faculdade de Farmácia da Universidade de Lisboa, a Postgraduate Degree in Laboratory Management and Auditor Training, and a PDD, Director Development Program Business Administration and Management at IESE.
Currently, she is the Chief Scientific Officer and a member of the board of directors at Laboratorios Rubió. She has robust knowledge in the pharmaceutical sector acquired over more than 17 years, which has given her great expertise in driving innovation through leadership roles and scientific research. In her current role at OWL Metabolomics, Dina’s comprehensive background will contribute to aligning the company’s R&D efforts with those of Laboratorios Rubió.
Dina Ferreira
More info
José M Mato, PhD
José M. Mato, completed his education at the Complutense University of Madrid and the University of Leiden. He conducted his research in the Netherlands, Switzerland, United States, and Spain before being appointed as Research Professor at the Spanish Council for Scientific Research (CSIC) in 1986. From 1992 to 1996, he was president of CSIC. In 2004, he received the National Prize for Research in Medicine in recognition of his contributions to the field of metabolism and liver disease.
He is the current general director of CIC bioGUNE and CIC biomaGUNE, both located in the Basque Country, Spain. He also played a pivotal role in the establishment of OWL Metabolomics, taking part of the Scientific Advisory Committee since the company was founded.
José M Mato, PhD
More info
Arun Sanyal, MD
Dr. Arun J. Sanyal, Professor of Medicine and Director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, currently serves as the Interim-Chair of the Division of Gastroenterology, Hepatology, and Nutrition at VCU/VCUHealth. His roles also include chairing the NIH MASH Clinical Research Network, the NIMBLE consortium, and the Liver Forum for MASH and fibrosis. His research primarily focuses on MASLD and MASH, as well as complications of cirrhosis and end-stage liver disease.
With continuous NIH funding since 1995, Dr. Sanyal has contributed significantly to the field with over 350 peer-reviewed publications. He has held key national and global positions, including Chair of the Hepatobiliary Pathophysiology Study Section of the NIH. His outstanding contributions have earned him prestigious awards such as the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Achievement Award from the AASLD. Currently, he is involved in numerous clinical trials, leading several phase 2B and 3 trials for MASH and complications of end-stage liver disease.
Arun Sanyal, MD
More infoVerified excellence
Certifications
We take great pride in the extensive recognition and certification from numerous health and governmental institutions we have received over the years. These certifications are a proof of our commitment to quality, innovation, and excellence in the field of metabolic sciences.
Latest updates
Latest news
Castellbisbal, Barcelona (España), +34 937 722 509 – labrubio@labrubio.com
